Search This Blog

Monday, April 20, 2026

Kyverna positive longer-term Phase 2 data for miv-cel in generalized myasthenia gravis

 

Kyverna Therapeutics reports positive longer-term Phase 2 KYSA-6 data for miv-cel in generalized myasthenia gravis

  • Data show deep, durable clinical responses maintained through 52 weeks in patients with generalized myasthenia gravis.
  • Favorable safety profile observed in KYSA-6, reinforcing confidence in the ongoing miv-cel Phase 3 program.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)